Connect your AI

Avalo Therapeutics AVTX Temporary Equity Shares Outstanding

Temporary Equity Shares Outstanding at other companies

Prospect CapitalPSEC

70.2M-1.3%

BillionToOne, Inc. BLLN

0-100%

Asset EntitiesASST

4.4M—

Perella Weinberg PartnersPWP

21.9M-16.3%

Prospect CapitalPSEC

833.2M-1.7%

Nextdoor Holdings, Inc.NXDR

$0—

Other financials

Income statement

Revenue$59.0K-69.3%

Gross profit$963.0K+8,855%

Operating income-$20.9M-42.5%

Net income-$19.6M-49.3%

EPS (diluted)-$0.98+21.6%

Balance sheet

Cash & equivalents$25.3M-79.8%

Total debt$328.0K-59.1%

Total equity$68.3M-44.3%

Total assets$99.9M-27.9%

Cash flow

Operating cash flow-$17.7M-87.1%

CapEx-—

Free cash flow-$15.0M-444%

Valuation

Market cap$946.18M+1,783%

Enterprise value$921.19M-1,342%

P/S1,892.4×+1,852×

Profitability

Gross margin182%+176pp

Operating margin-15,536.1%-17,275pp

Net margin-7,965.8%-10,750pp

FCF margin-11,123.8%-13,374pp

Returns & leverage

Return on equity-88.8%—

Debt / equity0×0.0×

Current ratio7.7×-14.9×

Where this comes from

Reported directly by Avalo Therapeutics in its filing.

Tagged under the XBRL concept us-gaap:TemporaryEquitySharesOutstanding.

The official record: Avalo Therapeutics’s 10-Q, filed May 13, 2026, on SEC EDGAR. View the filing →

Ask your AI about Avalo Therapeutics's temporary equity shares outstanding.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Harbor at dusk

Questions, answered.

What is Avalo Therapeutics's temporary equity shares outstanding?: Avalo Therapeutics (AVTX) reported temporary equity shares outstanding of 2 in Q1 2026.
How has Avalo Therapeutics's temporary equity shares outstanding changed year-over-year?: Avalo Therapeutics's temporary equity shares outstanding decreased by 0.0% year-over-year, from 2 to 2.